Cornea
Share your love
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement from Glaukos enabling the re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol. According to the company, under the updated labeling for iDose TR, physicians may now re-administer iDose…
Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula | Ophthalmology Times
(Image Credit: AdobeStock/pressmaster) Cloudbreak Pharma and the US Food and Drug Administration have completed an end-of-phase 2 meeting regarding the late-stage development of CBT-004 for the treatment of pinguecula. According to the company, this meeting helped to provide a “clear…
FDA approvals in 2025: What changed and why it matters for ophthalmologists | Ophthalmology Times
Editor’s Note: This content was generated with the assistance of AI. From first-in-class pharmacologic therapies to next-generation retinal durability strategies and less invasive surgical platforms, 2025 emerged as a pivotal year for the ophthalmic pipeline. Over the past 12 months,…
Q&A: What changed in residency education in 2025? Perspectives from training directors | Ophthalmology Times
Residency programs are adapting to evolving training requirements, new technologies, and changing trainee needs to better prepare future ophthalmologists. (Image credit: AdobeStock/WavebreakMediaMicro) Ophthalmology residency training is constantly evolving, and 2025 marked a year of notable developments that are shaping how…
Surgeon reflection: What patient case stayed with you in 2025? | Ophthalmology Times
Neda Shamie reflects on a 2025 case that reminded her how trust, patience, and communication are as critical as any surgical technique. (Image credit: AdobeStock/LIGHTFIELD STUDIOS) As the year draws to a close, many clinicians are taking stock of the…
Customized Clarity: Navigating IOL Options for Optimal Patient Care | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Tanner Ferguson, MD, and Taj Nasser, MD, FWCRS, discuss the management of astigmatism at the time of cataract surgery,…
Topical liposomal ozonated oil may be a useful treatment in neurotrophic keratopathy | Ophthalmology Times
Advances in topical therapies highlight new approaches to supporting corneal healing and infection control in neurotrophic keratopathy. (Image credit: AdobeStock/Pixel-Shot) Topical liposomal ozonated oil may play an antiseptic role in the management of neurotrophic keratopathy (NK), potentially serving as an…
Screening for Demodex blepharitis: Integrating best practices into routine eye care | Ophthalmology Times
(Image Credit: AdobeStock) Demodex blepharitis is more common than previously thought, and proper diagnosis and management are important for effective patient care. Anne M. Zaki, MD, a cornea specialist in private practice at Desert Eye Specialists in Peoria, Arizona, moderated…
Managing challenging pterygium removal: Amniotic membrane grafting strategies | Ophthalmology Times
(Image Credit: AdobeStock/Sangiao_Photography) Pterygium is a common ocular surface disorder characterized by a fibrovascular growth originating from the conjunctiva that extends onto the adjacent cornea (Figure).1 Its prevalence varies considerably across geographic regions. Because prolonged sun exposure is the main…